Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on January 30, 2020. The registrant is a Delaware corporation headquartered in Boulder, Colorado, with common stock trading on the Nasdaq Capital Market under the symbol MGEN. The filing reports on a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
This filing is an "Other Events" report and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on clinical trial updates.
Material Changes and Events
- Clinical Trial Update: The company announced new efficacy and safety data from the adult T-cell leukemia/lymphoma arm of its ongoing Phase 1 clinical trial for its drug candidate, cobomarsen.
- Conference Presentation: The data is scheduled to be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA, held from January 30 to February 1, 2020.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the context of the clinical trial data presentation. The primary content is the announcement of the data release.
Investor Verification Checklist
- Verify the specific efficacy and safety data points for cobomarsen in the adult T-cell leukemia/lymphoma arm (refer to Exhibit 99.1 Press Release).
- Confirm the company name is Miragen Therapeutics, Inc., as the input metadata incorrectly listed Viridian Therapeutics, Inc.
- Review the full text of the press release filed as Exhibit 99.1 for detailed clinical outcomes not summarized in this 8-K.